Supplementation with vitamin E in hyperlipidemic patients treated with diet and clofibrate. Effects on serum lipoprotein concentrations, plasma fatty acid composition and adipose tissue lipoprotein lipase activity.
Twelve hyperlipidemic patients on long term treatment with a lipid lowering diet enriched in polyunsaturated fatty acids and with clofibrate were supplemented with vitamin E (400 mg/day). The effect on serum lipoprotein concentration, plasma lipid fatty acid composition, and adipose tissue lipoprotein lipase activity was studied. No additional lipid-lowering effect was registered during a treatment period of 4 months. A slight increase in total serum cholesterol concentration and in high density lipoprotein concentration was probably attributable to seasonal variations in serum lipoprotein concentrations. No major changes of fatty acid composition in plasma cholesteryl esters or triglycerides were recorded. However, an increased relative amount of arachidonic acid and a reduced amount of palmitic acid in the plasma phospholipids after 2 months was possibly caused by the vitamin E therapy.
D000273:Adipose Tissue / Q000201:enzymology*; D000368:Aged; D002788:Cholesterol Esters / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D005227:Fatty Acids / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism* / Q000628:therapy; D008055:Lipids / Q000097:blood*; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014810:Vitamin E / Q000097:blood / Q000494:pharmacology*
D002788:Cholesterol Esters; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D008055:Lipids; D008074:Lipoproteins; D010743:Phospholipids; D014280:Triglycerides; D014810:Vitamin E; D008071:Lipoprotein Lipase; D002994:Clofibrate